GLP-1 medications can address several conditions, so patients may qualify for their use in various ways: Type 2 diabetes: Patients with an A1C of 6.5% or higher may be eligible for these medications to help regulate blood sugar
Recent studies suggest that glucagon receptor signaling is disrupted in NAFLD, indicating that supra-physiological glucagon receptor agonism might represent a new NAFLD treatment target
Journal of the International Society of Sports Nutrition, 12 (Suppl 1), P41
The short answer: In most cases, yes
When Express Scripts members are covered by participating health plans and employers, the program will continue to cap out-of-pocket costs for insulin and non-insulin diabetes treatments at $25 for up to a 34-day supply or $75 for a 90-day supply
Inspire and get inspired by an enthusiastic community of Noomers just like you with Noom Circles, Noom Vibe, and more